Icahn Boosts Stake in Amylin: Look for a Future Sale

It's been a while since we posted here. Due to the credit crisis we've been super busy at the main StreetInsider.com site. In addition, there haven't been too many 13Ds worth mentioning. We are going to start posting frequently again.

Yesterday, there was an interesting filing from one of our favorites Carl Icahn on Amylin Pharmaceuticals (AMLN). He's been a holder there for a long time, but now he is seeking to get a slate of 5 on the Board of Directors. We have great article over StreetInsider.com for premium members, discussing how "Like ImClone, Ichan Will Get Amylin Sold."

Comments

[10Q Detective:]

foolish to think that Icahn can do much to expedite the development of diabetic and obesity compounds in Amlyn’s portfolio. He might, however, be more ‘persuasive’ in convincing Bradbury and the board to sell the company to its diabetic partner, Eli Lilly!

blogs.bnet.com/secdocu...

Jan 30 10:37 AM

[BigOlDave:]

Lon's pumping his (very expensive) stock research service. Why does SA waste our time with these posts?

Jan 30 12:47 PM